Healthcare / Medical DevicesTaiwan
$60.10
+1.00 (+1.64%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 16%
FCF escenarios
weak_data · normalized FCF $-53.3M · quality 33.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
31/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.4B
P/E
300.5x
↑EV/EBITDA
29.4x
↑ROE
1.0%
↑Gross Margin
42.3%
↓Debt/Equity
0.90
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+9.6%
FCF CAGR
—
FCF margin
-8.1%
FCF / Net income
-6.89x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $661.4M · net income $7.7M · FCF $-53.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $661.4M | $661.4M | $538.9M | $537.1M | $502.1M |
| Net Income | $7.7M | $7.7M | $5.6M | $74.1M | $70.0M |
| EBITDA | $82.6M | $82.6M | $75.5M | $128.5M | $118.9M |
| EPS | — | — | 0.15 | 1.95 | 1.94 |
| Gross Margin | 42.3% | 42.3% | 43.5% | 57.3% | 50.7% |
| Operating Margin | 3.2% | 3.2% | -0.4% | 17.2% | 11.9% |
| Net Margin | 1.2% | 1.2% | 1.0% | 13.8% | 13.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.90 | 0.90 | 0.60 | 0.51 | 0.14 |
| Current Ratio | 2.58 | 2.58 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-53.3M | $-53.3M | $-173.0M | $-30.9M | $62.1M |
| Returns | |||||
| ROE | 1.0% | 1.0% | 0.8% | 9.3% | 10.8% |
| Valuation | |||||
| P/E | 300.50 | 300.50 | 539.39 | 49.33 | 34.02 |
| EV/EBITDA | 29.44 | 29.44 | 41.95 | 27.93 | 18.42 |
| P/B | 3.08 | 3.08 | 4.17 | 4.62 | 3.67 |
| Growth & Yield | |||||
| Revenue Growth | 22.7% | 22.7% | 0.3% | 7.0% | — |
| EPS Growth | — | — | -92.3% | 0.9% | — |
| Dividend Yield | 0.8% | 0.8% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-11.5%
Start / end P/E
n/dx → n/dx
EPS bridge
0.15 → n/d
Residual
-12.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.